The global Companion Diagnostic Market is dividedinto three categories: technology, indication, and geography. The market isdivided into immunohistochemistry, polymerase chain reaction (PCR), nextgeneration sequencing (NGS), in situ hybridization, and others based ontechnology type. The market is divided into three categories based onindication: oncology, neurology, and others. Lung cancer, colorectal cancer, breastcancer, blood cancer, and other cancers are divided under the oncologycategory. The market is divided into four regions: North America (the UnitedStates, Canada, and Mexico), Europe (Germany, France, the United Kingdom, andthe rest of Europe), Asia-Pacific (China, Japan, Australia, and the rest ofAsia-Pacific), and LAMEA (Latin America, Middle East, and Africa).
The PCR category now dominates the globalmarket in terms of technology, and this trend is expected to continue over theforecast period.
The next generation sequencing segment,on the other hand, is expected to grow rapidly during the forecast period,owing to key advantages such as higher sensitivity for detecting low-frequencyvariants, faster turnaround time for large sample volumes, and the ability tosequence hundreds to thousands of genes or gene regions at the same time, amongothers. Next-generation sequencing is used to detect Oncomine Dx Target Test,FoundationOne CDx, FoundationFocus CDxBRCA Assay, and other tests.
Significant changes in gene sequence andexpression patterns have been discovered in cancer research, which can be usedto develop targeted therapies. In addition, several biomarkers for variousmalignancies have been found, and Companion Diagnostic Market have beenestablished for them. Companion Diagnostic Market are frequentlyutilised in a variety of cancers, including lung cancer, colorectal cancer,breast cancer, and blood cancer, all of which are leading causes of death.
By Technology Type
- Immunohistochemistry
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- In Situ Hybridization
- Others
By Indication
- Oncology
- Neurology
- Others
Early detection of COVID-19 is becomingincreasingly important in the market, as it can aid in the identification ofthe best treatment for patients infected with the virus. The polymerase chainreaction (PCR) test, which uses nasopharyngeal swabs or other upper respiratorytract specimens, including throat swabs, is the most routinely used andreliable test for COVID-19 diagnosis. As a result, disease diagnosis utilisingpolymerase chain reaction (PCR) has become a primary emphasis for diseasemanagement. TScan Therapeutics and Qiagen signed a research licence and optionagreement in November 2020 to develop a COVID-19 immune response test.
The development of new biomarkers forvarious diseases, an increase in R&D of targeted therapies, an increase indemand for tailored medicine with growing awareness in developing countries,and a bigger number of unmet cancer care needs are all predicted to drive the CompanionDiagnostic Market. In September 2020, Roche, for example, launched a highlysuccessful SARS-CoV-2 antibody test with quick findings. Market growth islikely to be boosted by the launch of such highly effective diagnostic tests.
The outbreak of SARS-CoV-2 (COVID-19) in2020 was one of society's most serious public health catastrophes. Furthermore,in the setting of the highly contagious COVID-19 epidemic, lung cancer patientsposed a considerable obstacle in clinical diagnosis and therapeuticdecision-making. According to a study published in Annals of PalliativeMedicine Journal 2020 by Zhou Sha et al., the COVID-19 pandemic had asubstantial impact on oncological care, indicating the necessity forappropriate treatment decisions, sustained follow-up, and psycho-oncologicalsupport during the pandemic.
In the United States, the favourable reimbursement scenariofor breast cancer diagnostic systems is expected to facilitate their uptake.The Centers for Medicare & Medicaid Services (CMS) expanded next-generationsequencing coverage as a diagnostic tool for patients with germline (inherited)breast cancer in January 2020.
